|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Debes JD and Tindall DJ: Mechanisms of
androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al; TAX 327 Investigators. Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Madan RA, Pal SK, Sartor O and Dahut WL:
Overcoming chemotherapy resistance in prostate cancer. Clin Cancer
Res. 17:3892–3902. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jordan MA and Wilson L: Microtubules as a
target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Inoue T, Leman ES, Yeater DB and
Getzenberg RH: The potential role of purine-rich element binding
protein (PUR) alpha as a novel treatment target for
hormone-refractory prostate cancer. Prostate. 68:1048–1056. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zeng Y, Kulkarni P, Inoue T and Getzenberg
RH: Down-regulating cold shock protein genes impairs cancer cell
survival and enhances chemosensitivity. J Cell Biochem.
107:179–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li Y, Zeng Y, Mooney SM, Yin B, Mizokami
A, Namiki M and Getzenberg RH: Resistance to paclitaxel increases
the sensitivity to other microenvironmental stresses in prostate
cancer cells. J Cell Biochem. 112:2125–2137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pederson T: Half a century of ‘the nuclear
matrix’. Mol Biol Cell. 11:799–805. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Getzenberg RH, Konety BR, Oeler TA,
Quigley MM, Hakam A, Becich MJ and Bahnson RR: Bladder
cancer-associated nuclear matrix proteins. Cancer Res.
56:1690–1694. 1996.PubMed/NCBI
|
|
11
|
Partin AW, Getzenberg RH, CarMichael MJ,
Vindivich D, Yoo J, Epstein JI and Coffey DS: Nuclear matrix
protein patterns in human benign prostatic hyperplasia and prostate
cancer. Cancer Res. 53:744–746. 1993.PubMed/NCBI
|
|
12
|
Brünagel G, Vietmeier BN, Bauer AJ, Schoen
RE and Getzenberg RH: Identification of nuclear matrix protein
alterations associated with human colon cancer. Cancer Res.
62:2437–2442. 2002.PubMed/NCBI
|
|
13
|
Leman ES and Getzenberg RH: Nuclear
structure as a source of cancer specific biomarkers. J Cell
Biochem. 104:1988–1993. 2008. View Article : Google Scholar
|
|
14
|
Seruga B, Ocana A and Tannock IF: Drug
resistance in meta-static castration-resistant prostate cancer. Nat
Rev Clin Oncol. 8:12–23. 2011. View Article : Google Scholar
|
|
15
|
Kim JJ, Yin B, Christudass CS, Terada N,
Rajagopalan K, Fabry B, Lee DY, Shiraishi T, Getzenberg RH, Veltri
RW, et al: Acquisition of paclitaxel resistance is associated with
a more aggressive and invasive phenotype in prostate cancer. J Cell
Biochem. 114:1286–1293. 2013. View Article : Google Scholar
|
|
16
|
Shevchenko A, Wilm M, Vorm O and Mann M:
Mass spectrometric sequencing of proteins silver-stained
polyacrylamide gels. Anal Chem. 68:850–858. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yin B, Zeng Y, Wang X, Liu G, Zhang M and
Song Y: Expression and clinical significance of cancer-testis genes
in clear cell renal cell carcinoma. Int J Clin Exp Pathol.
7:4112–4119. 2014.PubMed/NCBI
|
|
18
|
Yin B, Liu G, Wang XS, Zhang H, Song YS
and Wu B: Expression profile of cancer-testis genes in transitional
cell carcinoma of the bladder. Urol Oncol. 30:886–892. 2012.
View Article : Google Scholar
|
|
19
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lonardo E, Hermann PC, Mueller MT, Huber
S, Balic A, Miranda-Lorenzo I, Zagorac S, Alcala S,
Rodriguez-Arabaolaza I, Ramirez JC, et al: Nodal/Activin signaling
drives self-renewal and tumorigenicity of pancreatic cancer stem
cells and provides a target for combined drug therapy. Cell Stem
Cell. 9:433–446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: Accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schutte B, Henfling M, Kölgen W, Bouman M,
Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et
al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp
Cell Res. 297:11–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moll R, Franke WW, Schiller DL, Geiger B
and Krepler R: The catalog of human cytokeratins: Patterns of
expression in normal epithelia, tumors and cultured cells. Cell.
31:11–24. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Linder S, Olofsson MH, Herrmann R and
Ulukaya E: Utilization of cytokeratin-based biomarkers for
pharmacodynamic studies. Expert Rev Mol Diagn. 10:353–359. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Knapp AC and Franke WW: Spontaneous losses
of control of cytokeratin gene expression in transformed,
non-epithelial human cells occurring at different levels of
regulation. Cell. 59:67–79. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Woelfle U, Sauter G, Santjer S, Brakenhoff
R and Pantel K: Down-regulated expression of cytokeratin 18
promotes progression of human breast cancer. Clin Cancer Res.
10:2670–2674. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kirfel J, Magin TM and Reichelt J:
Keratins: A structural scaffold with emerging functions. Cell Mol
Life Sci. 60:56–71. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Paramio JM and Jorcano JL: Beyond
structure: Do intermediate filaments modulate cell signalling?
BioEssays. 24:836–844. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Parekh H, Wiesen K and Simpkins H:
Acquisition of taxol resistance via P-glycoprotein- and
non-P-glycoprotein-mediated mechanisms in human ovarian carcinoma
cells. Biochem Pharmacol. 53:461–470. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liang Y, Meleady P, Cleary I, McDonnell S,
Connolly L and Clynes M: Selection with melphalan or paclitaxel
(Taxol) yields variants with different patterns of multidrug
resistance, integrin expression and in vitro invasiveness. Eur J
Cancer. 37:1041–1052. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yin B, Yang Y, Zhao Z, Zeng Y, Mooney SM,
Li M, Xu X, Song Y, Wu B and Yang Z: Arachidonate 12-lipoxygenase
may serve as a potential marker and therapeutic target for prostate
cancer stem cells. Int J Oncol. 38:1041–1046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
van der Horst G, Bos L and van der Pluijm
G: Epithelial plasticity, cancer stem cells, and the
tumor-supportive stroma in bladder carcinoma. Mol Cancer Res.
10:995–1009. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yin B, Zeng Y, Liu G, Wang X, Wang P and
Song Y: MAGE-A3 is highly expressed in a cancer stem cell-like side
population of bladder cancer cells. Int J Clin Exp Pathol.
7:2934–2941. 2014.PubMed/NCBI
|
|
34
|
Barak V, Goike H, Panaretakis KW and
Einarsson R: Clinical utility of cytokeratins as tumor markers.
Clin Biochem. 37:529–540. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Olofsson MH, Ueno T, Pan Y, Xu R, Cai F,
van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S,
et al: Cytokeratin-18 is a useful serum biomarker for early
determination of response of breast carcinomas to chemotherapy.
Clin Cancer Res. 13:3198–3206. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Demiray M, Ulukaya EE, Arslan M, Gokgoz S,
Saraydaroglu O, Ercan I, Evrensel T and Manavoglu O: Response to
neoadjuvant chemotherapy in breast cancer could be predictable by
measuring a novel serum apoptosis product, caspase-cleaved
cytokeratin 18: A prospective pilot study. Cancer Invest.
24:669–676. 2006. View Article : Google Scholar : PubMed/NCBI
|
